Treating HCV in HIV 2013: On the cusp of change

Valérie Martel-Laferrière; Douglas T. Dieterich

doi:10.1111/liv.12396

Treating HCV in HIV 2013: On the cusp of change

Valérie Martel-Laferrière
, Douglas T. Dieterich

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Treating hepatitis C virus (HCV) in HIV/HCV co-infected patients is a challenge. Even if the benefits of achieving a sustained virological response are clear, the rates achieved with the combination of pegylated-interferon and ribavirin are disappointing. The addition of direct acting antiviral agents (DAAs) to the treatment of hepatitis C is revolutionizing the treatment of HCV in mono-infected patients. Even if there have not been any agents approved for the treatment of co-infected patients, many studies specifically designed for this population are ongoing. This article reviews available data on the use of DAAs in co-infected patients and the challenges associated with these new drugs.

Original language	English
Pages (from-to)	53-59
Number of pages	7
Journal	Liver International
Volume	34
Issue number	SUPPL1
DOIs	https://doi.org/10.1111/liv.12396
State	Published - Feb 2014

Keywords

Co-infection
Direct acting antiviral agents
HIV
Hepatitis C

Access to Document

10.1111/liv.12396

Cite this

@article{70954495064a43229b4249d4173c5b56,

title = "Treating HCV in HIV 2013: On the cusp of change",

abstract = "Treating hepatitis C virus (HCV) in HIV/HCV co-infected patients is a challenge. Even if the benefits of achieving a sustained virological response are clear, the rates achieved with the combination of pegylated-interferon and ribavirin are disappointing. The addition of direct acting antiviral agents (DAAs) to the treatment of hepatitis C is revolutionizing the treatment of HCV in mono-infected patients. Even if there have not been any agents approved for the treatment of co-infected patients, many studies specifically designed for this population are ongoing. This article reviews available data on the use of DAAs in co-infected patients and the challenges associated with these new drugs.",

keywords = "Co-infection, Direct acting antiviral agents, HIV, Hepatitis C",

author = "Val{\'e}rie Martel-Laferri{\`e}re and Dieterich, \{Douglas T.\}",

year = "2014",

month = feb,

doi = "10.1111/liv.12396",

language = "English",

volume = "34",

pages = "53--59",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "SUPPL1",

}

TY - JOUR

T1 - Treating HCV in HIV 2013

T2 - On the cusp of change

AU - Martel-Laferrière, Valérie

AU - Dieterich, Douglas T.

PY - 2014/2

Y1 - 2014/2

N2 - Treating hepatitis C virus (HCV) in HIV/HCV co-infected patients is a challenge. Even if the benefits of achieving a sustained virological response are clear, the rates achieved with the combination of pegylated-interferon and ribavirin are disappointing. The addition of direct acting antiviral agents (DAAs) to the treatment of hepatitis C is revolutionizing the treatment of HCV in mono-infected patients. Even if there have not been any agents approved for the treatment of co-infected patients, many studies specifically designed for this population are ongoing. This article reviews available data on the use of DAAs in co-infected patients and the challenges associated with these new drugs.

AB - Treating hepatitis C virus (HCV) in HIV/HCV co-infected patients is a challenge. Even if the benefits of achieving a sustained virological response are clear, the rates achieved with the combination of pegylated-interferon and ribavirin are disappointing. The addition of direct acting antiviral agents (DAAs) to the treatment of hepatitis C is revolutionizing the treatment of HCV in mono-infected patients. Even if there have not been any agents approved for the treatment of co-infected patients, many studies specifically designed for this population are ongoing. This article reviews available data on the use of DAAs in co-infected patients and the challenges associated with these new drugs.

KW - Co-infection

KW - Direct acting antiviral agents

KW - HIV

KW - Hepatitis C

UR - https://www.scopus.com/pages/publications/84890864499

U2 - 10.1111/liv.12396

DO - 10.1111/liv.12396

M3 - Review article

C2 - 24373079

AN - SCOPUS:84890864499

SN - 1478-3223

VL - 34

SP - 53

EP - 59

JO - Liver International

JF - Liver International

IS - SUPPL1

ER -

Treating HCV in HIV 2013: On the cusp of change

Abstract

Keywords

Access to Document

Fingerprint

Cite this